HYDERABAD:Bharat Biotech has entered into a collaboration with US-based clinical stage biotech player Alopexx Inc for the co-development and commercialization of the latter’s proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low income and lower middle-income countries.
As part of the collaboration, the companies will co-develop and commercialize AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), in India and other licensed territories.PNAG is a substance found on the surface of a wide range of bacterial, fungal, and parasitic pathogens.
As part of the deal, Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories.
In pre-clinical studies, targeting PNAG the vaccine showed effectiveness in preventing and treating infections caused by over 15 different pathogens.
A phase I, first-in-human trial has been completed, demonstrating that AV0328 is well-tolerated with no serious adverse events observed. The vaccine induced antibodies capable of killing a wide range of PNAG-expressing pathogens, reaffirming its potential as a broad-spectrum antimicrobial solution, Bharat Biotech said.
Bharat Biotech executive chairman Dr Krishna Ella said the company would bring AV0328 to regions where it is most needed. “Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally,” he said.
Alopexx CEO Dr Daniel Vlock said the collaboration with Bharat Biotech was crucial not only for the advancement of AV0328, but would also significantly bolster Alopexx’s overall clinical programmes.
“This collaboration brings us one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial solutions, especially in low-and middle-income countries. To partner with a company with such vast experience and expertise in vaccine development is a significant validation of the value and potential of Alopexx’s technology,” Vlock added.
Alopexx Inc is a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and parasitic infections.
As part of the collaboration, the companies will co-develop and commercialize AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), in India and other licensed territories.PNAG is a substance found on the surface of a wide range of bacterial, fungal, and parasitic pathogens.
As part of the deal, Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories.
In pre-clinical studies, targeting PNAG the vaccine showed effectiveness in preventing and treating infections caused by over 15 different pathogens.
A phase I, first-in-human trial has been completed, demonstrating that AV0328 is well-tolerated with no serious adverse events observed. The vaccine induced antibodies capable of killing a wide range of PNAG-expressing pathogens, reaffirming its potential as a broad-spectrum antimicrobial solution, Bharat Biotech said.
Bharat Biotech executive chairman Dr Krishna Ella said the company would bring AV0328 to regions where it is most needed. “Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally,” he said.
Alopexx CEO Dr Daniel Vlock said the collaboration with Bharat Biotech was crucial not only for the advancement of AV0328, but would also significantly bolster Alopexx’s overall clinical programmes.
“This collaboration brings us one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial solutions, especially in low-and middle-income countries. To partner with a company with such vast experience and expertise in vaccine development is a significant validation of the value and potential of Alopexx’s technology,” Vlock added.
Alopexx Inc is a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and parasitic infections.